ALEXANDRIA, Va., Sept. 23 -- United States Patent no. 12,419,852, issued on Sept. 23, was assigned to Exerkine Corp. (Ontario, Canada).
"Method for treating lysosomal storage disease" was invented by Mark Tarnopolsky (Hamilton, Canada).
According to the abstract* released by the U.S. Patent & Trademark Office: "This application is directed to the use of a ketogenic agent, such as 1,3-butanediol, R-Beta-hydroxybutyl-R-Beta-hydroxybutyrate, or triheptanoin, in the treatment of an individual having a lysosomal storage disease, including Pompe disease. Compositions comprising ketogenic agents and metabolic enhancing agents for treating a lysosomal storage disease are also provided."
The patent was filed on Aug. 27, 2019, under Application No...